Relmada Therapeutics
RLMD
113 hedge funds and large institutions have $623M invested in Relmada Therapeutics in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 41 increasing their positions, 21 reducing their positions, and 13 closing their positions.
123% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 13
97% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $13.4M
95% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 21
33% more capital invested
Capital invested by funds: $467M → $623M (+$156M)
16% more funds holding
Funds holding: 97 → 113 (+16)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
39.73% less ownership
Funds ownership: 118.31% → 78.58% (-40%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$21M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$13.3M |
| 3 |
BlackRock
New York
|
+$11.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.57M |
| 5 |
RI
RTW Investments
New York
|
+$7.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$16.5M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$9.01M |
| 3 |
Morgan Stanley
New York
|
-$6.35M |
| 4 |
Millennium Management
New York
|
-$5.67M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.87M |
RLMD Hedge Fund Activity: Q1 2022 in Review
113 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2022, worth a combined $623M — up 33% from $467M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new RLMD positions and 13 closed out — a net gain of 16 holders — while 41 added to existing stakes and 21 trimmed.
The largest buyer was Cowen and Company, adding an estimated $21M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $16.5M sold.
- 113 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2022, up from 97 in Q4 2021.
- Funds reported $623M of Relmada Therapeutics stock for Q1 2022, up 33% quarter-over-quarter.
- 29 funds opened new Relmada Therapeutics positions in Q1 2022 and 13 closed out, a net change of +16 holders.
- The largest Relmada Therapeutics buyer in Q1 2022 was Cowen and Company, an estimated $21M added.
- The largest Relmada Therapeutics seller in Q1 2022 was Avidity Partners Management, an estimated $16.5M sold.
Based on aggregated 13F filings for Q1 2022.